Biomanufacturing Media
-
Deploying And Managing Cloud Microservices In A GxP Environment
2/6/2023
Check out this discussion on the benefits of microservice architecture and approaches for deploying and managing SaaS solutions utilizing microservice architecture in GxP regulated environments.
-
Simplify CPV And CPI, Accelerate Your Product's Time To Market
2/6/2023
Learn about best practices for meeting CPV and CPI requirements using purpose-built software that collects and transforms critical data for product lifecycle validation with two technology experts.
-
Create A Single Source Of Data Truth With Data Management Technology
2/6/2023
Learn how one leading biotech company achieved adopting new technology to establish a single source of truth across their diverse manufacturing network with compliant, scalable process data management technology.
-
Why Polar: A Day In The Life Of A Scientist
1/24/2023
Learn about a data management and collaboration platform that could make your scientists' work days easier.
-
Reimagining Data Management For Faster, Smarter BioProcess Development
1/24/2023
Discover solutions to create a digital data backbone and best practices for laying the foundation for advanced analytics to make process understanding easier and more efficient.
-
Achieving mRNA-LNP Delivery Beyond The Liver
11/28/2022
In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.
-
Q&A On LNP Cell-Specific Delivery
11/28/2022
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.
-
Defining A “Next-Gen” LNP
11/28/2022
Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their expectations on which scientific advancements/characteristics will be most important for LNP-delivery of mRNA/RNA cargo in the future.
-
Q&A On Formulation & Stability Of LNPs
11/28/2022
Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, address audience questions around the importance of drug substance and drug product stability in efficient delivery in this segment of the Bioprocess Online Live! event LNPs & Beyond: Opportunities in RNA Delivery.
-
mRNA’s Future Beyond The COVID Vaccines
11/28/2022
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, unpack which learnings can be adapted from ASO-LNPs to mRNA/LNPs and from mRNA vaccines to mRNA therapeutics. They also touch upon which learnings cannot be neatly carried over from these previous success stories.